TY - JOUR
T1 - Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3–5
T2 - is it significant?
AU - Prabhu, Ravindra Attur
AU - Mareddy, Aswani Srinivas
AU - Nagaraju, Shankar Prasad
AU - Rangaswamy, Dharshan
AU - Guddattu, Vasudeva
N1 - Funding Information:
This study was funded through a seed grant from Manipal Academy of Higher Education, India.
Publisher Copyright:
© 2019, Springer Nature B.V.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Purpose: To study the incidence of lactic acidosis due to metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stage 3–5. Methods: We estimated plasma lactate in patients of CKD stage 3 and worse who were continuing metformin on their own prior to stopping the drug. Result: Of 40 patients included, median duration of T2DM was 60 months (interquartile range IQR 24–120). The mean serum creatinine was 309.4 ± 159.1 µmol/L and mean eGFR was 27.82 ± 12.93 mL/min/1.73 m2 with 3 (7.5%), 16 (40%), 11 (27.5%) and 10 (25%) in CKD stages 3a, 3b, 4 and 5, respectively. They were receiving metformin for a median duration of 24 months (IQR 12.5–60), an average dose of 896 ± 350 mg per day. The median of plasma lactate was 1.36 mmol/L (IQR 1.11–1.75 mmol/L) with three (7.5%) having levels above normal, two (20%) in CKD stage 5 and one (9.1%) in stage 4. Conclusion: Metformin can be safely used in CKD stage 3 and with regular measurement of plasma lactate in later stages.
AB - Purpose: To study the incidence of lactic acidosis due to metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stage 3–5. Methods: We estimated plasma lactate in patients of CKD stage 3 and worse who were continuing metformin on their own prior to stopping the drug. Result: Of 40 patients included, median duration of T2DM was 60 months (interquartile range IQR 24–120). The mean serum creatinine was 309.4 ± 159.1 µmol/L and mean eGFR was 27.82 ± 12.93 mL/min/1.73 m2 with 3 (7.5%), 16 (40%), 11 (27.5%) and 10 (25%) in CKD stages 3a, 3b, 4 and 5, respectively. They were receiving metformin for a median duration of 24 months (IQR 12.5–60), an average dose of 896 ± 350 mg per day. The median of plasma lactate was 1.36 mmol/L (IQR 1.11–1.75 mmol/L) with three (7.5%) having levels above normal, two (20%) in CKD stage 5 and one (9.1%) in stage 4. Conclusion: Metformin can be safely used in CKD stage 3 and with regular measurement of plasma lactate in later stages.
UR - http://www.scopus.com/inward/record.url?scp=85064274219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064274219&partnerID=8YFLogxK
U2 - 10.1007/s11255-019-02136-y
DO - 10.1007/s11255-019-02136-y
M3 - Article
C2 - 30963454
AN - SCOPUS:85064274219
SN - 0301-1623
VL - 51
SP - 1229
EP - 1230
JO - International Urology and Nephrology
JF - International Urology and Nephrology
IS - 7
ER -
